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Once believed to represent a default pathway, the mo-
bilization of cargo from the endoplasmic reticulum (ER)
is now well established as a selective event that employs
exit signals to sort and concentrate cargo into vesicular
carriers (Bannykh et al. 1998). These vesicular carriers
and their cargo proteins continue through the secretory
pathway to the Golgi apparatus via a network of vesic-
ular-tubular clusters, which are discontinuous with the
ER but interconnected with one another. This network
has also been referred to as “the ER-Golgi intermediate
compartment” (ERGIC) or the “intermediate compart-
ment” (IC). Although several yeast mutants with selec-
tive-protein–transport defects have been defined, the re-
cent identification of ERGIC-53 as the gene responsible
for combined deficiency of coagulation factors V and
VIII is the first evidence for the existence of a cargo-
specific pathway in higher organisms. Here, we sum-
marize the process of vesicle formation and discuss the
role of the ERGIC in anterograde and retrograde trans-
port between the ER and the Golgi apparatus. We also
review current information about genetic defects in this
pathway and their role in human genetic disease.
Exit from the ER
Two types of coat proteins on vesicles are known to
participate in the transport between the ER and the
Golgi complex: coat proteins (COP) I (Harter 1995;
Schekman and Orci 1996; Gaynor and Emr 1997; Gay-
nor et al. 1998) and COPII (Schekman and Orci 1996;
Barlowe 1998; Matsuoka et al. 1998). COPII acts earlier
in the pathway, apparently driving the initial budding
of vesicles from the ER. COPII consists of the Sar1p
GTPase and a pair of protein complexes, Sec23p-Sec24p
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and Sec13p-Sec31p (the latter protein names reflect the
fact that the corresponding genes were first identified in
yeast defective in the secretory pathway). Mammalian
homologues of Sec23p and Sec13p localize to the ER
and to vesicles that derive from it. Because vesicle bud-
ding can be reconstituted from mammalian ER mem-
branes, by use of these purified components, and because
COPII vesicles can fuse with Golgi membranes, it was
concluded that COPII transports cargo from the ER to
the Golgi complex.
COPII-coated–vesicle formation begins when Sar1p
GTPase is recruited to an active zone of the ER
membrane, through a guanine-nucleotide–exchange re-
action catalyzed by the integral membrane glycoprotein
Sec12p. The membrane-bound activated Sar1p then re-
cruits the Sec23p-24p complex, after which the Sec13p-
31p complex binds to the membrane and forms vesicles.
This formation of a vesicle by COPII defines the first
compartmental boundary of the secretory pathway. Lit-
tle is known about how vesicle components are recog-
nized and packaged, but it appears that there is consid-
erable specificity in these interactions. These components
include “cargo” proteins—soluble or transmembrane
proteins that are destined for the cell surface or various
intracellular compartments—as well as various intrinsic
vesicle proteins that mediate the delivery of the cargo
and the recycling of membrane to the ER. In the latter
category are the v-SNARE (vesicle-soluble NSF attach-
ment-protein receptor) proteins (Springer and Schekman
1998). v-SNAREs are membrane-bound proteins that
interact with their cognate target-SNARE (t-SNARE)
proteins in acceptor organelles, such as the Golgi ap-
paratus or the plasma membrane. The specific interac-
tion between v- and t-SNARES ensures that vesicles fuse
only with the appropriate organelle.
The selection of cargo within a budding vesicle is de-
pendent on sorting signals—usually discrete peptide do-
mains of 4–25 residues—that are displayed on secretory
proteins (Rothman and Wieland 1996). A number of
different transport signals have been identified, including
some that target proteins for retrieval from the Golgi to
the ER (KDEL, KKXX, and XXRR) and others that
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Figure 1 ER to Golgi transport. This drawing depicts events involved in both anterograde and retrograde trafficking, between the ER
and the Golgi. COPII-coated vesicles, containing v-SNARES, ERGIC-53, and cargo proteins, bud off from the ER (unblackened arrows). The
COPII vesicles shed their COPII coats, which are replaced by COPI coats. Vesicles then fuse to form components of the ERGIC, and ERGIC
clusters move in a microtubule-dependent manner toward the Golgi and either fuse, to form the cis-Golgi, or transfer their cargo via COPI-
coated vesicles. v-SNARES, ERGIC-53, and other proteins are recycled back to the ER in COPI-coated vesicles, which bud from both the
ERGIC and Golgi apparatus (blackened arrows).
signal transport from the Golgi to endosomes or lyso-
somes (propeptide, mannose 6-phosphate, and tyrosine-
rich dileucine motifs). Such transport signals may inter-
act directly or indirectly with COP proteins during
packaging (Campbell and Schekman 1997; Aridor et al.
1998; Bannykh and Balch 1998; Kuehn et al. 1998).
Recent studies suggest that the fidelity of cargo re-
cruitment into vesicles may be regulated by a group of
transmembrane proteins, the products of the p24 gene
family (Stamnes et al. 1995; Fiedler et al. 1996). Yeast
and human cells express 16 p24-homologues, some of
which carry a dilysine retrograde transport signal. Mem-
bers of the p24 family may function as links between
cargo proteins and the vesicular coat. Emp24p, a mem-
ber of the p24 gene family from yeast, is a component
of the COPII-coated, ER-derived transport vesicles
(Schimmo¨ller et al. 1995). A strain of yeast lacking
Emp24p fails to transport certain cargo glycoproteins,
such as the soluble secreted protein invertase and the
plasma-membrane protein Gas1p. Because Emp24-neg-
ative cells secrete a-factor, carboxypeptidase Y, or acid
phosphatase with normal kinetics, Schimmo¨ller and col-
leagues provided the first evidence for cargo-pro-
tein–specific defects in loading or transporting COPII
vesicles.
Transit to the Golgi Apparatus
In the most widely accepted model, once budding of
COPII-coated vesicles has occurred the COPII coat is
shed, and the vesicles fuse to form the ERGIC (see fig.
1; Presley et al., 1997; Scales et al., 1997; Bannykh et
al. 1998; Bannykh and Balch 1998). It is at this point
that the other coat-protein complex, COPI, becomes as-
sociated with new budding vesicles (Harter 1995; Schek-
man and Orci 1996; Gaynor and Emr 1997; Gaynor et
al. 1998). When COPI was first found, in preparations
of in vitro–derived mammalian Golgi vesicles, it was
believed to mediate anterograde transport of cargo
through the Golgi stack. The COPI complex, consisting
of the seven COPs (a, b, b′, g, d, , and z), self-assembles
in the cytoplasm and binds to membranes en bloc. It has
been proposed that GTP-bound ADP-ribosylation factor
(ARF), followed by the heptameric COPI complex bind
to ERGIC membranes and initiate the budding of COPI-
coated vesicles. Genetic analyses on yeast have also iden-
tified all of the COPI subunits and ARF; each of these
genes is essential for viability except for SEC28, which
encodes e-COP.
The relative contributions of COPI to anterograde and
retrograde transport have been the subject of significant
debate in recent years (Harter 1995; Gaynor and Emr
1997; Schekman and Mellman 1997; Gaynor et al.
1998). COPI clearly plays a critical role in Golgi-to-ER
retrograde transport (reviewed by Schekman and Orci
1996; Gaynor and Emr 1997; Gaynor et al. 1998), as
indicated by both genetic and biochemical experiments.
A dilysine (KKXX) motif that permits type I–membrane
proteins to be retrieved to the ER (Jackson et al. 1990)
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was found to bind specifically to COPI proteins in vitro.
Furthermore, a screen for yeast mutants defective for
KKXX-mediated retrieval (ret mutants) identified three
COPI subunits (a, d, z) as products of RET genes. All
COPI mutants, including some that are designated as
“Sec mutants” because they were first identified as a
result of their defects in anterograde transport, are lack-
ing in KKXX-mediated retrieval.
Although the direct role of COPI in retrograde (Golgi
to ER) transport is widely accepted, the same cannot be
said for its role in anterograde (ER to Golgi) transport.
Several lines of evidence support a role for COPI in
anterograde transport (reviewed by Harter 1995; Gay-
nor and Emr 1997; Gaynor et al. 1998). In mammalian
cells, inhibition of COPI function results in a block in
ER-to-Golgi transport. In yeast, the COPI subunits b,
b′, and g (products of sec26, 27, and 21) were initially
identified through the characterization of mutants de-
fective in anterograde transport. Recently, Gaynor and
Emr (1997) generated temperature-sensitive sec21 mu-
tants in which carboxypeptidase Y and a-factor accu-
mulated in the ER, whereas other cargo proteins
(HSP150 and invertase) were secreted normally or sorted
properly to the vacuole. These observations demonstrate
that COPI is not directly required for anterograde trans-
port of all secreted proteins. Perhaps retrieval of limiting
transport factors by COPI is required for the efficient
packaging of a select subset of cargo proteins into an-
terograde ER-derived COPII vesicles.
Recent evidence suggests that COPII and COPI act
sequentially in protein transport. Scales et al. (1997)
visualized exocytic transport from the ER to the Gol-
gi in living cells, using a chimera of the temperature-
sensitive vesicular stomatitis virus glycoprotein and
green-fluorescent protein (ts-G-GFPct). When shifted to
permissive temperature, ts-G-GFPct concentrates into
COPII-positive structures close to the ER. These struc-
tures build up, to form an intermediate compartment of
tubular clusters that contain the KDEL receptor (which
mediates the retrieval of resident ER proteins from the
ERGIC), as well as the marker protein ERGIC-53. This
compartment appears to be the site at which COPII pro-
teins are replaced by COPI. COPI, but not COPII, re-
mains associated with these tubular clusters as they
move, in a microtubule-dependent manner, toward the
Golgi complex, eventually fusing with each other to form
the cis-Golgi network. On the basis of these results,
Scales and colleagues argue that COPII vesicles form at
defined ER-export sites and then fuse to form the
ERGIC. The loss of COPII and its replacement with
COPI allow vesicles derived from this compartment to
interact with the microtubule cytoskeleton and to be
transported to the Golgi apparatus. Their data are con-
sistent with either a direct role for COPI in anterograde
transport or with the model of Gaynor and Emr (1997),
in which COPI mediates the retrieval of vesicles and
thus is indirectly necessary for ongoing anterograde
membrane traffic between the ER and the Golgi.
Insights from Combined Coagulation Factors V and
VIII Deficiency
Coagulation factor V (FV) and factor VIII (FVIII) are
both required for the efficient function of the blood co-
agulation system. Combined factors V and VIII defi-
ciency is a distinct autosomal recessive disorder, first de-
scribed by Oeri et al. (1954) (for review see Seligsohn
1989). Affected patients demonstrate a moderate bleed-
ing tendency, in association with plasma levels of FV
and FVIII (both antigen and activity) in the range of
5%–30% of normal. Since the original report, 189 pa-
tients belonging to 64 families have been described
(Seligsohn 1989; Nichols et al. 1998, 1999; Neerman-
Arbez et al. 1999). Approximately one-half of the fam-
ilies described thus far are of Mediterranean origin, in-
cluding 15 Italian and nine Israeli families. This disorder
appears to be particularly prevalent among Jews of Mid-
dle Eastern and Sephardic origin. Among Israeli indi-
viduals with those backgrounds the disease occurs in ∼1:
100,000 (Seligsohn 1989). Inheritance is autosomal
recessive and is distinct from coinheritance of both FV
deficiency (parahemophilia) and FVIII deficiency (he-
mophilia A). Because of the high incidence of consan-
guinity, affected individuals were assumed to be ho-
mozygous at a locus that in some manner uniquely
regulates the expression of these two specific proteins.
FV is synthesized primarily in megakaryocytes and
hepatocytes and is found in the plasma and a-granules
of platelets as a 330-kDa single-chain polypeptide (for
review of factor V and VIII biosynthesis see Kaufman
1998). FVIII is most likely synthesized in the hepatocyte
and reticuloendothelial cells, although the major phys-
iologic source for the in vivo expression of this clotting
factor remains unknown. FVIII is proteolytically proc-
essed, on secretion from the cell, to form a heterodimer.
Both factors circulate in plasma as inactive precursors
that are activated through limited proteolysis and sub-
sequently assemble with their substrates (prothrombin
and factor X) and enzymes (factor Xa and factor IXa)
on a negatively charged phospholipid surface. The nat-
ural anticoagulant protein, protein C, functions by pro-
teolytically inactivating FV and FVIII, shutting off fur-
ther thrombin generation.
FV and FVIII are homologous proteins with a con-
served domain organization. The “A” domains of both
proteins also demonstrate homology to the plasma cop-
per-binding protein, ceruloplasmin. FV and FVIII un-
dergo similar and extensive posttranslational modifica-
tions including formation of conserved disulfide bonds,
addition of multiple asparagine- and serine/threonine-
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linked oligosaccharides, and sulfation at several tyrosine
residues. Despite similarities in structure and function,
FV and FVIII differ markedly in plasma concentration,
with the quantity of FV exceeding that of FVIII by ∼40-
fold. These differences appear to be partly because of a
higher level of FV gene transcription, as well as greater
FV mRNA stability and more efficient protein secretion.
The considerably less-efficient secretion of FVIII, relative
to that of FV, may be explained in part by FVIII inter-
action with BiP and other chaperones. BiP, a member of
the 70-kDa heat-shock–protein family, exhibits a pep-
tide-dependent ATPase activity. Its expression is induced
by the presence of unfolded or unassembled protein sub-
units within the ER. FVIII release from BiP and transport
out of the ER requires high levels of intracellular ATP.
In contrast, FV does not associate with BiP and does not
require high levels of ATP for secretion.
Two other chaperones, calnexin (CNX) and calreti-
culin (CRT) (Pipe et al. 1998), also differ in their inter-
actions with the two clotting factors. CNX and CRT
are endogenous ER-lectin molecules that bind to nascent
glycoproteins. FVIII secretion depends on its interaction
with both BiP and CNX. Upon translocation into the
lumen of the ER, FVIII immediately binds BiP and is
released after ATP hydrolysis. Misfolded FVIII molecules
subsequently interact, through their N-linked oligosac-
charides, with CNX and CRT (for a review of the ER
quality control system see Ashkenas and Byers 1997;
Riordan 1999 [in this issue]). Only fully folded FVIII
escapes the chaperone-mediated retention mechanism
and is finally transported to the Golgi apparatus and out
of the cell. FV does not exhibit these extensive inter-
actions with BiP and CNX during its transport through
the ER.
ERGIC-53 and the Molecular Basis of Combined
Factors V and VIII Deficiency
The molecular basis for combined FV/FVIII deficiency
had been a puzzle since its first description in 1954 (for
review see Seligsohn 1989). Chance coinheritance of
classic hemophilia A (FVIII deficiency) and parahemo-
philia (FV deficiency) has been reported in four families.
However, this explanation could not account for the
majority of patients with combined deficiency, for whom
the genetic pattern reflects simple autosomal recessive
inheritance resulting from a defect in a single gene. As
noted above, FV and FVIII are both proteolytically in-
activated by activated protein C (APC). Thus, deficiency
of protein-C inhibitor, leading to unopposed increased
activity of APC, seemed a logical explanation for this
disorder when first reported. However, subsequent stud-
ies documented normal levels of protein-C inhibitor in
these patients and demonstrated that the initial obser-
vation of decreased levels was a result of laboratory
artifact. The normal half life of exogenous coagulation
factors administered to these patients argued against an
accelerated clearance mechanism and suggested that this
disorder might be due to a common defect in biosyn-
thesis or secretion. However, this latter explanation was
difficult to reconcile with the markedly different plasma
levels and patterns of expression for these two proteins.
To determine the molecular basis of the disorder, we
first localized the gene for combined FV/FVIII deficiency
to the long arm of chromosome 18, in nine unrelated
Jewish families of Sephardic and Middle Eastern origin,
using a homozygosity mapping approach (Nichols et al.
1997). This localization was subsequently confirmed in
an independent study of 19 families from Iran, Pakistan,
and Algeria (Neerman-Arbez et al. 1997). Recent po-
sitional cloning efforts have shown that the disease gene
encodes ERGIC-53, a component of the intermediate
compartment. Two founder mutations, each predicted
to completely inactivate ERGIC-53, accounted for the
disease in all nine Israeli families (Nichols et al. 1998).
Subsequently, an additional 54 families have been an-
alyzed for ERGIC-53 mutations (Neerman-Arbez et al.
1999; Nichols et al. 1999), and a total of 17 different
mutations have been identified in 37 of the 54 families.
All but one of the mutations are either nonsense or
frameshift alleles whose truncated protein products
would be predicted to lack normal ERGIC-53 function.
The only missense mutation substitutes a threonine for
the initiator methionine. Surprisingly, no mutation could
be identified in 17 (∼30%) of 64 families analyzed to
date. Biochemical and genetic data suggest that a sig-
nificant subset of combined FV/FVIII deficiency results
from mutations in at least one alternative locus.
Schweitzer and coworkers developed a panel of mon-
oclonal antibodies to ERGIC membranes and showed
that the ERGIC-53 epitope localizes to this intracellular
structure (reviewed by Itin et al. 1996; Kappeler et al.
1997). ERGIC-53 is a type 1–transmembrane protein,
which exist as homodimers and homohexamers. ERGIC-
53 contains regions of homology to lectins from legu-
minous plants (Fiedler and Simons 1994) and it binds
to glycoproteins in a calcium-dependent, mannose-se-
lective manner (Arar et al. 1995; Itin et al. 1996). Its
amino acid sequence contains determinants for antero-
grade transport and a dilysine ER-retrieval signal, that
together are thought to result in constitutive recycling
among the ER, ERGIC, and Golgi apparatus (Itin et al.
1996). The protein was identified independently as
MR60, a mannose-specific membrane lectin isolated
from human monocytes (Arar et al. 1995), and close
homologues have been identified in rat (p58), Xenopus
laevis, and Caenorhabditis elegans (GenBank Z81097).
The yeast protein Emp47p, which shows significant ho-
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mology to ERGIC-53 (Schro¨der et al. 1995), recycles
between the ER and the Golgi apparatus but localizes
predominantly to Golgi.
An antibody to the ERGIC-53 cytoplasmic tail blocks
the transport of vesicular stomatitis virus glycoprotein,
from ER to Golgi, and the recruitment of COPI to the
intermediate compartment in permeabilized cells (Tis-
dale et al. 1997). Thus, ERGIC-53 may be required for
the coupled exchange of COPII and COPI coats during
segregation of anterograde and retrograde transported
proteins. In addition, mutagenesis studies demonstrate
that the cytoplasmic tail of ERGIC-53 interacts directly
with the COPII coat component Sec23p, which may di-
rect it to vesicles that bud from the ER (Kappeler et al.
1997). This interaction with ERGIC-53 may mark the
Sec23p complex for transport, whereupon Sec23p-ac-
tivated cargo may be concentrated in a patch of
membrane by the interaction of the Sec23p complex with
the Sec13p complex. Accumulation of such coat patches
could deform the membrane, creating a bud and ulti-
mately a transport vesicle. ERGIC-53 may be the first-
known example of a cargo protein for which such a
sorting mechanism into COPII vesicles occurs. These re-
sults suggested that ERGIC-53 is essential for the general
transport of glycoproteins through the secretory path-
way. However, the limited phenotype of combined FV/
FVIII deficiency indicates that ERGIC-53 is only re-
quired for the efficient secretion of a specific subset of
glycoproteins (Nichols et al. 1998). To date, no other
abnormalities have been identified in patients with com-
bined FV/FVIII deficiency, but it seems likely that defects
in at least a limited subset of other proteins may also
be present.
Vollenweider and colleagues studied a recombinant
mutant ERGIC-53, in which AlaAla had replaced the
di-phenylalanine motif (Vollenweider et al. 1998). This
mutant failed to recycle and it accumulated in the ER,
where it exerted a dominant-negative effect on the en-
dogenous normal ERGIC-53. A selective delay in secre-
tion of the lysosomal protein cathepsin C was observed,
consistent with the proposed role of ERGIC-53 as a
specific sorting receptor. Measurement of cathepsin C
levels in patients has not yet been reported. However,
the absence of any other apparent disease phenotype in
combined FV/FVIII deficiency patients, outside of the
bleeding disorder, suggests that the defect in the targeting
of cathepsin C or other similar proteins may be too
subtle to produce a significant functional abnormality.
In addition, the observation of decreased but significant
residual FV and FVIII activity in these patients suggests
that ERGIC-53 enhances the efficiency of a sorting event
during the transport of these proteins, but it is not ab-
solutely required for their secretion.
Conclusions
The unexpected identification of ERGIC-53 as the
gene responsible for combined FV/FVIII deficiency
clearly establishes ERGIC-53 as a component of the ER-
Golgi transport machinery that is required for the effi-
cient export of coagulation factors V and VIII. This is
the first demonstration of a cargo-specific pathway for
protein export from the ER in mammalian cells. How-
ever, the apparently normal levels observed in these pa-
tients for most other plasma proteins demonstrate that
ERGIC-53 is not essential for the integrity of the inter-
mediate compartment or the more general process of
protein export. The identification of the genetic defect
in the subset of patients with FV/VIII deficiency but with
intact ERGIC-53 may unmask additional critical com-
ponents of this unique transport pathway.
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